Clinical study of carmofour concurrent with radiotherapy for esophageal cancer

Objective:To study the tolerance,tolerated dose,adverse effects and initial efficacy of carmofour concurrent with radiotherapy in patients with esophageal cancer.Methods:Total 36 patients,3 patients were excluded because of allergy to carmofour,33 patients completed the treatment.Conformal radiotherapy and conventional radiotherapy were given.Carmofour was given from 100mg Tid to 200mg Tid during the whole radiotherapy.Results:The main adverse effects were esophagitis,hematoxicity and dermoreaction,which patients could tolerate.The CR rate was 15.2%,PR rate was 63.6%,NC rate was 21.2%.The overall response rate was 78.8%.The median survival time was 14 months and 2-year-survival rate was 25.4%.Conclusion:The patients with esophageal cancer can tolerate radiotherapy concurrent with carmofour.In the concurrent chemoradiotherapy,carmofour with 200mg three times every day was tolerable.